Goldman Sachs analysts added UCB (UCBJF) to the firm’s European Conviction List as part of its monthly update. The firm believes UCB offers a “rare opportunity” within European biopharma to own a blockbuster launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UCBJF: